Sign in with Google
bullish
AptaBio Therapeutics (293780 KS): Promising, Innovative, and First-In-Class Pipeline
500 Views05 Nov 2021 09:50
SUMMARY
- AptaBio Therapeutics (293780 KS) shares surged 28% in last one month, increasing its one-year gain to 213% versus KOSPI’s gain of 26%. Share price was driven by presentation of clinical progress of AptaBio’s pipeline at a virtual meeting held from October 7 to 9, 2021.
- By leveraging on its two proprietary platform technologies, NOX inhibitor discovery platform and Aptamer-drug conjugate platform, AptaBio has developed eight new clinical candidates for complications of diabetes mellitus and three new candidates for anticancer agents. Its lead candidate APX-115 is also being studied as an oral COVID-19 treatment.
- This insight has analyzed the strength and potential of AptaBio’s late-stage pipeline to find whether further stream is left after a spectacular rally in share price in last one year.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Tencent To Acquire Nexon? Time and Price Lining Up for a Final Deal?
- MV Australia Resources Index Rebalance: Two Adds, Float & Capping Changes
- MarketVector Vietnam Local Index Rebalance: One Add, Capping & Float Changes
- HLB Merger Arb's Unique Timing Dynamics for a Juicy 8% Swap Spread
- HEW: Geopolitics Blow Hot And Warm
Top Unpaywalled Insights
More »Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- AptaBio Therapeutics (293780 KS): Near-Term Cash Crunch Is Clouding Promising Prospects of Pipeline22 Sep 2022
- AptaBio Therapeutics (293780 KS): Promising, Innovative, and First-In-Class Pipeline05 Nov 2021
x